Discounted Cash Flow
Cytek Biosciences, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $92.8m | $19.4m | $13.6m | 20.9% | $0.11 |
| 2021 | $128.0m (37.8%) | $3.0m (-84.4%) | $266.0k (-98.0%) | 2.4% (-88.7%) | $0.00 (-100.0%) |
| 2022 | $164.0m (28.2%) | $2.5m (-17.9%) | $-22.0m (-8362.8%) | 1.5% (-36.0%) | $0.02 |
| 2023 | $193.0m (17.7%) | $-12.1m (-589.0%) | $633.0k (102.9%) | -6.3% (-515.6%) | $-0.09 (-550.0%) |
| 2024 | $200.5m (3.9%) | $-6.0m (50.4%) | $21.9m (3352.4%) | -3.0% (52.3%) | — |
| 2025 | $201.5m (0.5%) | $-66.5m (-1005.3%) | $-8.8m (-140.1%) | -33.0% (-999.6%) | — |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.